Meet the team test
Germán Schuager
Pablo Rovedo
Luciana Di Tocco
Daniella Janssen
Laura Dominguez
Sebastian Talamoni
Lisandro Massera
Guillermo Gerard
Augusto Galán
Matias Romero
Pablo Curulli
Rodrigo Crespin
Sebastián Diaz
Hans Eeckhout
Melissa Gol
Kees Hörchner
More info
Nelson+ B.V. is a Joint Venture of the the RADventure group and the Institute for DiagNostic Accuracy (iDNA). Through their extensive experience in lung cancer screening, ICT, screening workflow and data management solutions, the Nelson+ platform was developed.
The RADventure Group is highly specialised in delivering tailor-made ICT solutions both for commercial and public companies to support their primary processes. Their solutions are shaped in close cooperation with their customers in a process in which everyone can focus on their own craftsmanship. They have more than 30 years of experience with large-scale screening programs like the Dutch national Breast Cancer program (approximately one million participants per year), and the Dutch National Cervical cancer screening program.
The quality and experience of their employees and an innovative, proven technology approach guarantee their customers solid and state-of-the-art systems. The smart reuse of software and sensible sourcing guarantees value for money. This is how RADventure enables its customers to focus on their business goals.
The RADventure Group is ISO 9001:2015 certified guaranteeing customers and partners a continuous high-quality service with proven standards and a constant focus on the improvement of services. In addition, RADventure is committed to protecting the environment in compliance with environmental laws and practices of the communities where it operates.
Read more: https://www.radventure.com/
The institute for DiagNostic Accuracy (iDNA) is a Contract Research Organization specialized in early stage lung cancer, and researching new technologies for the early detection and treatments of lung cancer, with comorbidities in cardiovascular diseases (CVD) and Chronic Obstructive Pulmonary Disease (COPD)/emphysema. Key to the early detection of lung cancer are high quality lung cancer screening programs and therefore iDNA wants to set the ‘’golden standard’’ for worldwide lung cancer screening. Not only do they offer A to Z guidance for the lung cancer screening implementation process itself, they are also on the research frontline in this area of expertise and offer educational solutions for nodule management as well. Partners are provided with newly developed software solutions, such as data tracking systems and e-Learning tools for radiologists.
iDNA has a Health Economics and Outcomes Research (HEOR) division specialising in the field of lung cancer screening, They can provide support for any lung cancer screening related HEOR questions which is strengthened by the collaborations with their academic partners.
Erasmus MC (main applicant) and iDNA (NL) are part of a consortium executing the European lung cancer screening trial: 4-IN-THE-LUNG-RUN (4-ITLR). The goal of the study is to evaluate personalised strategies in recruitment, screening intervals, smoking cessation and other co-morbidity (coronary heart disease and COPD) prevention strategies.
Read more: https://www.i-dna.org/
